Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Shares Issued (2021 - 2025)

Xeris Biopharma Holdings' Shares Issued history spans 5 years, with the latest figure at $690000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Shares Issued fell 44.53% year-over-year to $690000.0, compared with a TTM value of $1.5 million through Dec 2025, up 22.19%, and an annual FY2025 reading of $1.5 million, up 22.19% over the prior year.
  • Shares Issued for Q4 2025 was $690000.0 at Xeris Biopharma Holdings, up from -$5.0 million in the prior quarter.
  • The five-year high for Shares Issued was $30.0 million in Q1 2022, with the low at -$30.0 million in Q4 2022.
  • Average Shares Issued over 5 years is $1.8 million, with a median of $549000.0 recorded in 2023.
  • Biggest YoY gain for Shares Issued was 959.04% in 2025; the steepest drop was 604.65% in 2025.
  • Tracing XERS's Shares Issued over 5 years: stood at $26.6 million in 2021, then plummeted by 212.64% to -$30.0 million in 2022, then soared by 98.17% to -$549000.0 in 2023, then surged by 326.59% to $1.2 million in 2024, then crashed by 44.53% to $690000.0 in 2025.
  • Per Business Quant, the three most recent readings for XERS's Shares Issued are $690000.0 (Q4 2025), -$5.0 million (Q3 2025), and $972000.0 (Q2 2025).